Can capmatinib shrink tumors?

Capmatinib (Capmatinib) is a targeted therapy drug, mainly used to treat MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC). This specific mutation is associated with abnormal activation of MET kinase, which is involved in the growth, differentiation and migration of tumor cells. The mechanism of action of capmatinib includes inhibiting the activity of MET kinase, thereby interfering with the growth signaling of cancer cells.

Clinical trial data show that capmatinib shows significant efficacy in METExon14skipping mutantNSCLC patients. Among them, an important efficacy performance is that the drug can cause tumor shrinkage, also known as the objective response rate. This means that a large proportion of patients who received capmatinib experienced significant tumor reduction, indicating that the drug had an inhibitory effect on tumor growth.

Capmatinib's tumor-shrinking effect is achieved through its ability to targetMETkinase. METExon 14 Tumors in patients with skipping mutations are often very sensitive to abnormal activation of MET kinases, and the inhibition of capmatinib can interfere with this abnormal signaling pathway, thereby slowing, inhibiting or even reversing tumor growth.

It is worth noting that while patients are using capmatinib, doctors will regularly monitor and evaluate the drug to ensure the efficacy of the drug and adjust the treatment plan in a timely manner. Tumor shrinkage is not only an important treatment indicator, but also closely related to the patient's survival and quality of life. Therefore, capmatinib provides an innovative and promising treatment option for patients with METexon14skipping mutantNSCLC through its ability to shrink tumors.

Capmatinib is not currently available in China, so patients cannot purchase it domestically and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive. Generic drugs on the market abroad are much cheaper, mainly Laos generic drugs, the price is around 3,000 to 4,000 yuan, and the ingredients of original drugs and generic drugs are basically the same.